Levofloxacin: Clinical Trials

265 trials of Levofloxacin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

151 completed, 49 unknown, 22 terminated, 18 not yet recruiting. 87 Phase 3, 74 Phase 4, 46 Not applicable, 42 Phase 2, 20 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 387Completed 64, Unknown 8, Terminated 5, Active not recruiting 4, Recruiting 3, Withdrawn 2, Not yet recruiting 1
Phase 474Unknown 28, Completed 25, Terminated 9, Not yet recruiting 5, Recruiting 4, Withdrawn 2, Active not recruiting 1
Not applicable46Completed 20, Not yet recruiting 11, Unknown 7, Recruiting 3, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Withdrawn 1
Phase 242Completed 31, Terminated 3, Unknown 3, Active not recruiting 2, Recruiting 2, Not yet recruiting 1
Phase 120Completed 16, Terminated 2, Unknown 2
Early Phase 12Terminated 1, Unknown 1

Follow Levofloxacin: new trials by email Literature Review of Levofloxacin trials Research Report on Levofloxacin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vonoprazan High-Dose Dual VS Levofloxacin Concomitant
Vonoprazan, Levofloxacin 500mg - Helicobacter Pylori Infection, Peptic Ulcer Disease
Phase 4Not yet recruitingDamascus Hospital1502026-11-012026-06-03
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin) - Brucellosis, Osteoarticular Brucellosis
Not applicableNot yet recruitingThe First Affiliated Hospital of Shihezi University1502026-11-012026-10-21
Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin - Brucellosis
Not applicableNot yet recruitingThe First Affiliated Hospital of Shihezi University2002026-11-012026-10-21
A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis
MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis
Phase 3Not yet recruitingSeoul National University Hospital2942026-10-012026-06-30
Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE)
Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin - Brucellosis, Osteoarthritis
Not applicableWithdrawnThe First Affiliated Hospital of Shihezi University2026-10-012026-10-27
Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery
Levofloxacin, Moxifloxacin - Cataract, Postoperative Endophthalmitis
Not applicableNot yet recruitingAssiut University932026-09-262026-09-30
Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
Levofloxacin, Usual Care - Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Phase 2Not yet recruitingUniversity of Manitoba752026-09-012026-06-29
Efficacy and Safety of Piclosept in the Complex Treatment of Neonatal Dacryocystitis
Picloxidine, Levofloxacin, Standardized lacrimal sac massage - Neonatal Dacryocystitis, Congenital Nasolacrimal Duct Obstruction
Phase 4Active not recruitingKazakh Eye Research Institute902026-08-252026-10-15
Rationale of Subcutaneous Levofloxacin Infiltration as an Adjunct for Surgical Site Infection Prevention in Emergency Laparotomy
Levofloxacin - Surgical Site Infection (SSI)
Not applicableNot yet recruitingSylhet M.A.G.Osmani Medical College902026-08-012026-07-13
Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women
Standard dose rifampicin, High dose rifampicin, Standard dose isoniazid - Tuberculosis Infection, Healthy Volunteer
Phase 1CompletedMcGill University Health Centre/Research Institute of the McGill University Health Centre602026-06-012026-11-02
Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB
Bedaquiline, Isoniazid, rifapentine, Levofloxacin - Tuberculosis, Latent
Phase 2 / Phase 3RecruitingJohns Hopkins University25302026-05-082026-10-20
Enhanced Treatment Strategy for Disseminated MAC Infection in HIV Patients: A Randomized Controlled Trial
Standard Triple Therapy, Experimental: Standard Triple Therapy Plus Fluoroquinolone - Opportunistic Infections, HIV Related, Disseminated Mycobacterium Avium Complex Infection
Not applicableNot yet recruitingShanghai Public Health Clinical Center1242026-04-302026-05-13
Levofloxacin Prophylaxis to Prevent First Febrile Neutropenia in Pediatric ALL During Induction Phase
Levofloxacin, Placebo - Neutropenic Fever, Acute Lymphoblastic Leukemia
Phase 4TerminatedGadjah Mada University492026-01-012026-10-01
Comparison of Two Treatment Regimens of Helicobacter Pylori Infection
Clarithromycin, Levofloxacin - Helicobacter Pylori Infection
Phase 4Not yet recruitingRehman Medical Institute - RMI1562025-12-012025-06-15
6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province
bedaquiline, Delamanid (DLM), Linezolid (LZD) - Treat to Target, Treatment Duration
Not applicableNot yet recruitingWuhan Pulmonary Hospital522025-09-302025-09-30
A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
bedaquiline, Pretomanid (Pa), linezolid - Efficacy and Safety
Not applicableNot yet recruitingWuhan Pulmonary Hospital2002025-09-012025-08-17
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days - Helicobacter Pylori Infection
Phase 4Not yet recruitingManuel Coelho da Rocha1602025-09-012024-12-20
Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection
Clarithromycin 500 mg, Amoxicillin 1 g, Omeprazole 40 mg - H Pylori
Phase 4Not yet recruitingRehman Medical Institute - RMI1282025-07-012025-06-27
Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea
Piperacillin/Tazobactam, Piperacillin/tazobactam + Levofloxacin - Severe Community-acquired Pneumonia (sCAP)
Not applicableNot yet recruitingCHOSEOK YOON1002025-06-152025-05-18
Shorter and Safer Treatment Regimens for Latent TB
rifampin standard arm, rifampin double dose, levofloxacin and rifapentine - Tuberculosis Infection, Latent
Phase 2 / Phase 3RecruitingMcGill University Health Centre/Research Institute of the McGill University Health Centre18002025-06-102026-05-11

Showing 20 of 265. Sign in to see all of them.

Conditions studied

Community-Acquired Pneumonia (16)  ·  Urinary Tract Infections (14)  ·  Pneumonia (12)  ·  Infections (11)  ·  Tuberculosis, Multidrug-Resistant (11)  ·  Tuberculosis (10)  ·  Tuberculosis, Pulmonary (9)  ·  Bacterial Infections (7)  ·  Cataract (6)  ·  Lung Diseases (6)  ·  Prostatitis (6)  ·  Appendicitis (5)  ·  Bronchitis, Chronic (5)  ·  Pneumonia, Bacterial (5)  ·  Pyelonephritis (5)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (24)  ·  Shandong University (7)  ·  Damascus Hospital (6)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (6)  ·  Seoul National University Hospital (5)  ·  Shanghai Jiao Tong University School of Medicine (5)  ·  Bayer (4)  ·  Pfizer (4)  ·  Sanofi (4)  ·  Ain Shams University (3)  ·  Beijing Chest Hospital (3)  ·  Boston University (3)  ·  Kaohsiung Veterans General Hospital. (3)  ·  NTC srl (3)  ·  National Taiwan University Hospital (3)

Countries

United States (56)  ·  China (44)  ·  Italy (15)  ·  France (13)  ·  Spain (13)  ·  Canada (12)  ·  Taiwan (12)  ·  Egypt (11)  ·  Germany (11)  ·  Russia (11)  ·  South Africa (11)  ·  South Korea (11)  ·  India (9)  ·  Pakistan (9)  ·  Greece (7)

Top investigators

Xiuli Zuo, MD,PhD (4)  ·  Marouf M Alhalabi, MD (3)  ·  Ping-I Hsu, Bachelor (3)  ·  David Prior (2)  ·  Dick Menzies, MD (2)  ·  Francesco Bandello, Prof. (2)  ·  George G Zhanel, PhD, FCCP (2)  ·  Hong Lu, M.D. (2)  ·  Li Yanqing, MD, PhD (2)  ·  Lindsay E Nicolle, MD, FRCPC (2)

Results publications

PMID 39382091, PMID 12039901, PMID 12145720, PMID 12749509, PMID 12946763, PMID 12955634, PMID 14986270, PMID 15276398, PMID 15329363, PMID 15530127, PMID 15557948, PMID 1559306, PMID 15840453, PMID 16148284, PMID 16236878, PMID 16420547, PMID 16631047, PMID 16776446, PMID 16965625, PMID 16982292, PMID 17133154, PMID 17178300, PMID 17261234, PMID 17313438, PMID 17509029, PMID 17531690, PMID 17696583, PMID 17854602, PMID 17880755, PMID 17901791, PMID 18042477, PMID 18061594, PMID 18070980, PMID 18211932, PMID 18242357, PMID 18419482, PMID 18446147, PMID 18462108, PMID 18508226, PMID 18702902, PMID 18787216, PMID 18818959, PMID 19036672, PMID 19128645, PMID 19238021, PMID 19286178, PMID 19419343, PMID 19564361, PMID 19588358, PMID 19740418

NIH funding

2015 (2), 2008 (1), 2014 (1), 2017 (1), 2023 (1), R01HD074944 (1), R01HL117074 (1), U01AI100805 (1), U01AI152980 (1), U10CA095861 (1)